Prestige Biologics Co., Ltd. (KOSDAQ:334970)

South Korea flag South Korea · Delayed Price · Currency is KRW
3,730.00
+80.00 (2.19%)
At close: Aug 6, 2025, 3:30 PM KST
2.19%
Market Cap289.63B
Revenue (ttm)6.71B
Net Income (ttm)-32.95B
Shares Out77.75M
EPS (ttm)-472.27
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume56,905
Average Volume202,772
Open3,635.00
Previous Close3,650.00
Day's Range3,625.00 - 3,730.00
52-Week Range3,235.00 - 7,830.00
Beta0.99
RSI39.36
Earnings Daten/a

About Prestige Biologics

Prestige Biologics Co., Ltd. specializes in the development and production of biologic agents and biosimilars. Its product candidates include Herceptin for breast and stomach cancer; Avastin for colon, lung, and ovarian cancers; Humira for arthritis; PBP1510 for pancreatic cancer; Denosumab for bone loss, osteoporosis; Aflibercept for macular edema and metastatic colorectal cancer; Eculizumab for atypical haemolytic uremic syndrome; Ipilimumab for metastatic melanoma; and PBP1710 for solid tumors. Prestige Biologics Co., Ltd. was formerly known... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2015
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 334970
Full Company Profile

Financial Performance

In 2024, Prestige Biologics's revenue was 2.17 billion, an increase of 24.24% compared to the previous year's 1.75 billion. Losses were -29.37 billion, -25.53% less than in 2023.

Financial Statements

News

There is no news available yet.